Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) – Investment analysts at Jefferies Financial Group issued their FY2023 EPS estimates for Kezar Life Sciences in a report issued on Tuesday, March 14th. Jefferies Financial Group analyst M. Raycroft anticipates that the company will earn ($1.27) per share for the year. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.15) per share. Jefferies Financial Group also issued estimates for Kezar Life Sciences’ FY2024 earnings at ($1.42) EPS, FY2025 earnings at ($1.54) EPS and FY2026 earnings at ($1.49) EPS.
KZR has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Kezar Life Sciences in a report on Thursday. Wells Fargo & Company decreased their price target on shares of Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, January 3rd. Finally, William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a research report on Wednesday.
Kezar Life Sciences Trading Down 1.6 %
Insider Buying and Selling
In other Kezar Life Sciences news, major shareholder Morningside Venture Investment sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $6.88, for a total transaction of $275,200.00. Following the completion of the transaction, the insider now owns 5,447,993 shares of the company’s stock, valued at $37,482,191.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 248,276 shares of company stock valued at $1,708,683 over the last three months. Corporate insiders own 7.80% of the company’s stock.
Institutional Investors Weigh In On Kezar Life Sciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its position in shares of Kezar Life Sciences by 8.3% during the 4th quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock valued at $135,000 after purchasing an additional 1,461 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Kezar Life Sciences by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 140,148 shares of the company’s stock worth $987,000 after purchasing an additional 1,608 shares during the period. The Manufacturers Life Insurance Company boosted its position in Kezar Life Sciences by 11.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 20,633 shares of the company’s stock valued at $145,000 after buying an additional 2,040 shares during the period. Dimensional Fund Advisors LP boosted its position in Kezar Life Sciences by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 277,928 shares of the company’s stock valued at $4,619,000 after buying an additional 2,130 shares during the period. Finally, Arizona State Retirement System raised its holdings in shares of Kezar Life Sciences by 17.5% in the 4th quarter. Arizona State Retirement System now owns 14,469 shares of the company’s stock valued at $102,000 after purchasing an additional 2,156 shares in the last quarter. Hedge funds and other institutional investors own 84.03% of the company’s stock.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.